From Cell Line Development to Commercial Manufacturing
Abzena’s presentation at World ADC 2017 given by Campbell Bunce – Senior Vice President Technical Operations.
Abzena PLC’s Annual Report 2017
The Company’s Annual Report for the year ended 31 March 2016 was released on 15 June 2016
Abzena’s corporate fact sheet
This brochure contains an overview of Abzena’s range of services from discovery to GMP manufacturing.
More information on Abzena’s Composite Protein™ technology. Protein Deimmunisation Technical Flyer
Information on a our PEGylation technologies, including a TheraPEG case study on the PEGylation of interferon (IFN) a-2b
More information on our antibody humanisation and deimmunisation technology, including a case study on the deimmunisation of an anti-CTLA-4 antibody. Download the technical flyer : Composite-Human-Antibodies-Technical-Flyer.pdf
Further information on Abzena’s accurate and sensitive ex vivo T cell epitope identication technology including example results.
© Abzena PLC | Registered Number: 08957107 | VAT Number: 125470235